EMERYVILLE, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter ended September 30, 2017, after the market close, and will host a corporate update conference call and webcast on Tuesday, November 7, 2017 at 4:30 PM Eastern Time.
Tuesday, November 7th @ 4:30 PM Eastern Time/1:30 PM Pacific Time
Toll Free: 888-211-9963
Conference ID: 6163936
Replays, available through November 21, 2017:
Replay PIN: 6163936
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com